智擎：公告董事會通過解除 子公司PharmaEngine Europe SARL之經理人競業禁止 鉅亨網新聞中心2015-08-13 16:39:29 第二條 第21款1.董事會決議日:104/08/132.許可從事競業行為之經理人姓名及職稱:Alain Herrera, Managing Director 3.許可從事競業行為之項目:Alain Oncology Consulting Director; Nanobiotix S.A. Independent Director; IDDI Independent Director; GR-Transfert Independent Director; AVEC Foundation Independent Director4.許可從事競業行為之期間:任職PharmaEngine Europe SARL經理人之職務期間5.決議情形（請依公司法第32條說明表決結果）:經主席徵詢全體出席董事無異議照案通過6.所許可之競業行為如屬大陸地區事業之營業者，經理人姓名及職稱（非屬大陸地區事業之營業者，以下請輸〝不適用〞）:不適用7.所擔任該大陸地區事業之公司名稱及職務:不適用8.所擔任該大陸地區事業地址:不適用9.所擔任該大陸地區事業營業項目:不適用10.對本公司財務業務之影響程度:無11.經理人如有對該大陸地區事業從事投資者，其投資金額及持股比例:無12.其他應敘明事項:無
Alain Herrera, MD, is currently Consultant in Oncology and Associate Director at Kephren. He has created Alain Oncology Consulting (AOC) in November 2008 after heading the oncology business at Sanofi-Aventis for nearly 10 years where he was Vice President responsible for Global Oncology Business Strategy and Development (2007-2008) and Head of Global Oncology Franchise (1998-2007). Alain contributed to the worldwide registration of oxaliplatin (Eloxatin®) and rasburicase (Fasturtec®/Elitek®) as well as the Gastric and Head & Neck indications for docetaxel (Taxotere®). Before joining Sanofi he was Chairman of Chiron Therapeutics Europe (now part of Novartis) Director of Chiron B.V, Corporate Vice President and Member of Management Council of Chiron Corporation and Managing Director at Pierre Fabre Oncology Laboratories. While at Roger Bellon (Rhône Poulenc), he was involved in evaluating the licensing of irinotecan from Yakult Co., Ltd (Japan) and was responsible for its early clinical development. Herrera has been a Hematologist Consultant at Antoine Beclere Hospital and Beaujon Hospital (since 1991) and Senior Resident, assistant to Prof. Pierre Boivin (Beaujon Hospital/University Paris VII). Herrera has published and lectured extensively as an invited speaker at national and international oncology meetings. He has authored numerous manuscripts in addition to contributing to numerous review articles and book chapters Herrera is an active member of ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology) and serves on the Executive Committee of ESH (European School of Hematology).
PharmaEngine Appoints Dr. Alain Herrera as Senior Advisor March 04, 2013 TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEngine, Inc. (TWO: 4162) announces today the appointment of Alain Herrera, MD, as Senior Advisor. Dr. Herrera will advise us on our clinical strategy and operations, as well as our corporate strategy, licensing and alliance management. PharmaEngine believes that the addition of Dr. Herrera will open a new page of clinical and corporate development for PharmaEngine."I am very pleased to have this opportunity to expand our collaboration with Dr. Herrera, and I believe that his global pharmaceutical industry experience will assist us in fulfilling our goal to be recognized as one of the successful international pharmaceutical companies based in Taiwan." Prior to founding his own consultancy firm, Alain Oncologie Consulting, Dr. Herrera headed the global oncology business at sanofi-aventis for ten years, as Vice President, Global Oncology Business Strategy and Development, and contributed to the worldwide registration of Oxaliplatin（Eloxatin®）and Rasburicase（Fasturtec®/Elitek®）, as well as the gastric and head & neck indications for Docetaxel（Taxotere®）. Other positions include Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories. While at Roger Bellon (Rhône Poulenc), he was involved in evaluating the licensing of irinotecan from Yakult Co., Ltd (Japan) and was responsible for its early clinical development."Dr. Herrera who was introduced to us by Prof. Aimery de Gramont (Chief of Oncology Department, Saint-Antoine Hospital, Paris, France) joined our Scientific Advisory Board since 2008, and has been instrumental in advising our clinical and business strategies," said C. Grace Yeh, Ph.D., President and Chief Executive Officer of PharmaEngine. "I am very pleased to have this opportunity to expand our collaboration with Dr. Herrera, and I believe that his global pharmaceutical industry experience will assist us in fulfilling our goal to be recognized as one of the successful international pharmaceutical companies based in Taiwan." Dr. Herrera said, "I am very happy to reinforce my collaboration with PharmaEngine. Since I started working with PharmaEngine more than 4 years ago, I realized that PharmaEngine has a professional team that not only successfully managed the worldwide development of PEP02, but also implemented a unique network of high level investigators from Taiwan, Asia, USA and Europe. I thank very much PharmaEngine for giving me an opportunity to involve such exciting projects to optimally develop innovative compounds in oncology globally."
About PharmaEngine, Inc. (TWO: 4162) PharmaEngine, Inc. is a biopharmaceutical company established in Taipei, Taiwan in 2003. PharmaEngine adopts the business model of "no research, development only" and focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases. The lead project PEP02 (nanoliposomal irinotecan, aka MM-398) which was licensed to Merrimack Pharmaceuticals, Inc., (Cambridge, MA, USA), is in a global phase III study for the treatment of metastatic pancreatic cancer; the second is PEP503 (crystalline hafnium oxide, aka NBTXR3) from Nanobiotix, Inc. (Paris, France); and the third was a collaboration with Guangzhou BeBetter Medicine Technology, Co., Ltd. (Guangzhou, China). For further information, please visit the Company's website at http://www.pharmaengine.com.
Posts
No comments:
Post a Comment